RP:TSX.V; REPCF:OTCQB

RepliCel Life Sciences Inc.

RepliCel Life Sciences Inc. is a regenerative medicine company focused on developing autologous cell therapies that address conditions caused by a deficit of healthy cells required for normal healing and function. The Companyís product pipeline is comprised of two ongoing clinical trials (RCT-01: tendon repair and RCS-01: skin rejuvenation) as well as its RCH-01: hair restoration product under exclusive license by Shiseido Company for certain Asian countries. All product candidates are based on RepliCelís innovative technology, utilizing cell populations isolated from a patientís healthy hair follicles. The Company has also developed a proprietary injection device (RCI-02) optimized for the administration of its products and licensable for use with other dermatology applications.
RP:TSX.V REPCF:OTCQB

Expert Comments:

Douglas Loe, Echelon Growth Partners (11/2/16)
"RepliCel Life Sciences Inc. reported T4W returns of +49% after announcing the close of the firmís $4.3M private placement. . .performance observed is not just that data point alone; RepliCel is nearing clinical milestones in H216 and H117, specifically with the firmís 10-patient Phase I/II trial, evaluating the autologous non-bulbar dermal sheath cell therapy RCT-01 in patients with Achilles tendinosis. Data from this trial is expected by end of this year. . .a 17-patient skin rejuvenation Phase I/II trial in Germany could release interim sixmonth RCS-01 efficacy data by FQ117."

Douglas Loe, Echelon Growth Partners (9/28/16)
"RepliCel Life Sciences Inc. provided two clinical and financial updates. First, the firm announced the intention of settling the firmís debt to certain creditors through the issuance of 719,368 share-and-warrant units. . .second, the firm provided an update on its regulatory activities in Japan, as it concerns partner Shiseido (4911-JP, NR) and the firmís autologous dermal sheath cup cell therapy RCH-01 for androgenetic alopecia. . .the firm noted RCH-01 is currently under clinical investigation at two hospitals, with the trial and the product manufactured by Shiseido. . .the firm notes that early commercialization of the product is possible in Japan."

"I do like RepliCel Life Sciences Inc., a micro-cap, Canadian, regenerative medicine company with a novel technology developing autologous cell therapies. What's interesting about RepliCel is that it has four novel programs on the go, and management has secured a partnership with Shiseido Company in Japan to fund its alopecia trials. RCH-01 for pattern baldness could be on the market in 2018. The company has developed a dermal injector device, RCI-02, to pair with its therapeutic approach. It will file for CE mark approval of the dermal injector in the European Union (EU) later this year, and I think the product will be on the market in Europe in 2017. Management has been able to derisk this little company in a way many small companies haven't been able to do. . .[the dermal injector] is a novel instrument with extreme precision that sources the cells in the scalp. It has an analgesic delivery capability built in so it can simultaneously anesthetize the skin and obtain autologous dermal sheath cells. It will have many applications. . .RepliCel won't market the product itself, but will partner that out. The company could have the alopecia therapy on the market in Japan in 2018, and the dermal injector could be on the market in the EU in 2017. . .the device is a catalyst. Even though RepliCel will have data in the alopecia and tendon repair indications later this year, I think dermal injector may carry more weight because the market may realize it represents the fastest route to commercialization and revenues, which would help the company mitigate some of its cash burn. The adoption and costs to market the device are much less than they would be for developing and commercializing a therapeutic." read more >

More Expert Comments

Experts Following This Company

Alan Leong, CEO – BioWatch News
Douglas Loe, Analyst – Euro Pacific Canada
Eden Rahim, Portfolio Manager and Options Strategist – Next Edge Capital, Theta Strategies Capital

The information provided above is from analysts, newsletters, the company and other contributors.

RepliCel Life Sciences Inc. is a sponsor of Streetwise Reports.†The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Investing Highlights
 
Data announcements from 3 different clinical trials in Q1 2017
 
Biotech company focused on large aesthetic and sports injury markets
 
Small-cap biotech company expected to be generating revenue in 2018
catalyst Calendar
RepliCel Life Sciences Inc. Content